ClinicalTrials.gg
CompletedNCT01461928MabCuteUpdated Aug 6, 2019Results posted

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

A Phase 3 interventional study of Chemotherapy (Induction Period) and Rituximab in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 180 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
692
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
5th of 171
692 · median 38
Started
2011
with 5 others
Phase 3
29 of 178
none open now
Registered
125th of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 5th largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2011, is one of 29 in phase 3, and was the 125th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This multicenter, randomized, open-label, parallel-group study will evaluate the efficacy and safety of subcutaneously administered rituximab in comparison with observation only as maintenance therapy in participants with relapsed or refractory indolent Non-Hodgkin's lymphoma (NHL). All participants will receive induction therapy with rituximab (375 milligrams per square meter [mg/m\^2] intravenously [IV] in Cycle 1, then 1400 mg subcutaneous [SC] every 3-4 weeks) plus standard chemotherapy for 6-8 months; followed by 24 months of maintenance I period with rituximab (1400 mg SC every 8 weeks). Participants completing therapy and showing partial or complete response will be randomized to receive either rituximab (1400 mg SC every 8 weeks) or observation with no treatment during maintenance II period and will be followed for at least 15 months. Anticipated time on study treatment is until disease progression, unacceptable toxicity or end of study, whichever occurs first.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed Cluster of Differentiation 20-positive (CD20+) follicular NHL Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma) according to World Health Organization (WHO) classification system
  • Participants must have received and must have or been refractory to, one or more lines of adequate therapy prior to enrollment, including at least one line consisting of immunotherapy and/or chemotherapy and/or radiotherapy
  • (ECOG) performance status less than or equal to (\<=) 2

Exclusion criteria

Exclusion Criteria:

  • Transformation to high-grade lymphoma
  • Aggressive lymphoma (for example, mantle cell lymphoma [MCL])
  • Presence or history of central nervous system (CNS) lymphomatous disease
  • Other within 5 years prior to enrollment, except for curatively treated carcinoma in situ of the cervix, squamous cell carcinoma of the skin or basal cell skin cancer, or cervical carcinoma Stage 1B or less, breast cancer in situ or localized prostate cancer Stage T1c if treated with curative intent and relapse- and -free for at least 2 years prior to enrollment
  • Inadequate hematological, hepatic or renal function
  • Known (HIV) infection
  • Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active or C)
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
692 participants (actual)

Study arms

  • Other
    Maintenance II Period Observation Only

    Participants will receive standard chemotherapy regimen in combination with 375 mg/m\^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.

    Drug: Chemotherapy (Induction Period) · Drug: Rituximab

  • Experimental
    Maintenance II Period Rituximab

    Participants will receive standard chemotherapy regimen in combination with 375 mg/m\^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).

    Drug: Chemotherapy (Induction Period) · Drug: Rituximab

Interventions

  • DrugChemotherapy (Induction Period)

    Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.

  • Participants will receive rituximab according to the regimen specified in individual arm.

    Also known as: Rituxan, MabThera, RO0452294

06

What researchers measure

Primary outcomes

  1. Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

    Progression free survival from randomization (PFSrand) is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed. The Observation arm did not include one participant with AE outcome of death reported retrospectively 2 months after discontinuation from study (censored as having no event on Day 456 post-randomization).

    Time frame: From randomization (Maintenance II) up to disease progression or death, whichever occurs first (up to approximately 24 months)

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious AEs, and Infusion/Administration-related Reactions (IRRs/ARRs)

    An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Not all AEs were followed up for the randomized Observation arm. Only Serious AEs and AE grade 3-5 (obtained retrospectively) were collected for this arm. Therefore arms are not comparable overall.

    Time frame: From day of first rituximab induction dose up to day of disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)

  2. Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

    Event-Free Survival was measured from the day of first rituximab Induction dose through Maintenance I and Maintenance II rituximab arm until the date of any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g. disease progression, toxicity, patient preference, initiation of new anti-lymphoma treatment, or death). Treatment discontinuation was considered as an event and was not applicable to the randomized observation arm.

    Time frame: From day of first rituximab induction dose up to day of any treatment failure, including disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)

  3. Time to Next Lymphoma Treatment (TNLT)

    Time to next lymphoma treatment (TNLT) is defined as the time from date of first rituximab induction dose to the date date of first documented intake of any new antilymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc.).

    Time frame: From day of first rituximab induction dose up to any new lymphoma treatment (up to approximately 87 months)

  4. Overall Survival

    Overall survival from first induction treatment (OSRegist) is defined as the time from date of first rituximab induction dose to the date of death, irrespective of cause. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed.

    Time frame: From day of first rituximab induction dose up to death (up to approximately 87 months)

  5. Maintenance II: Overall Survival

    Overall survival from randomization (OSrand) is defined as the time from date of randomization to the date of death, irrespective of cause.

    Time frame: From randomization (Maintenance II) up to death (up to approximately 24 months)

  6. Percentage of Participants With Partial or Complete Tumor Response (PR/CR) Assessment at End of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

    Overall response rate is defined as the proportion of responders at the end of the Induction period. A responder is defined as a participant experiencing either CR or PR tumor response according to the Cheson response criteria for indolent lymphoma or the recommendations for Waldenström's macroglobulinemia.

    Time frame: From day of first rituximab induction dose up to end of induction period (up to approximately 8 months)

  7. Maintenance I: Percentage of Participants With Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

    Time frame: From day of first rituximab induction dose up to end of Maintenance I period (up to approximately 32 months)

  8. Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

    Progression free survival from first induction treatment (PFSregist) is defined as the time from date of first rituximab induction dose to the date of first documented disease progression or death by any cause, whichever occurs first.

    Time frame: From day of first rituximab induction dose up to disease progression or death, whichever occurs first (up to approximately 87 months)

07

Results

Posted Aug 6, 2019

Participant flow

Participants were identified for potential recruitment using pre-screening enrolment logs.

Induction (up to 8 Months)
Participant flow — Induction (up to 8 Months)
MilestoneAll ParticipantsMaintenance II - Arm A (Rituximab)Maintenance II - Arm B (Observation Only)
Started69200
Completed49400
Not completed19800
Withdrew: Adverse event7600
Withdrew: Death300
Withdrew: Lost to follow-up500
Withdrew: Physician decision900
Withdrew: Withdrawal by subject1800
Withdrew: Disease progression4500
Withdrew: Eligibility criteria deviation1000
Withdrew: Completed induction, no maint i received1100
Withdrew: Not responding to treatment1100
Withdrew: Termination of study in switzerland100
Withdrew: Treated before eligibility was confirmed100
Withdrew: Sponsor decision100
Withdrew: Protocol deviation200
Withdrew: Prednisolone given prior to enrolment100
Withdrew: Cycle 7 rituximab not given in error100
Withdrew: Promotor request100
Withdrew: Exceeded time limit for next cycle100
Withdrew: Medical advisor request100
Maintenance I (24 Months)
Participant flow — Maintenance I (24 Months)
MilestoneAll ParticipantsMaintenance II - Arm A (Rituximab)Maintenance II - Arm B (Observation Only)
Started49400
Completed27600
Not completed21800
Withdrew: Death300
Withdrew: Withdrawal by subject3200
Withdrew: Lost to follow-up200
Withdrew: Diseases progression9100
Withdrew: Adverse event7000
Withdrew: Physician decision900
Withdrew: Did not meet randomization criteria200
Withdrew: Did not perform scheduled assessment200
Withdrew: Delay in rituximab administration100
Withdrew: Not compliant100
Withdrew: Did not meet criteria500
Maintenance II (15 Months)
Participant flow — Maintenance II (15 Months)
MilestoneAll ParticipantsMaintenance II - Arm A (Rituximab)Maintenance II - Arm B (Observation Only)
Started0138138
Completed0115111
Not completed02327
Withdrew: Adverse event020
Withdrew: Death0108
Withdrew: Physician decision004
Withdrew: Lost to follow-up010
Withdrew: Moved to another town010
Withdrew: Disease progression003
Withdrew: Withdrawal by subject098
Withdrew: Changed physician in another hospital001
Withdrew: Squamous lung carcinoma001
Withdrew: Withdrew informed consent001
Withdrew: Refused to be transferred to other site001

Outcome measures

PrimaryMaintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

Progression free survival from randomization (PFSrand) is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed. The Observation arm did not include one participant with AE outcome of death reported retrospectively 2 months after discontinuation from study (censored as having no event on Day 456 post-randomization).

Time frame:
From randomization (Maintenance II) up to disease progression or death, whichever occurs first (up to approximately 24 months)
Reported as:
Median · Months
Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
MonthsMaintenance II - Arm A (Rituximab)Maintenance II - Arm B (Observation Only)
Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's MacroglobulinemiaNA (NA to NA)NA (39.75 to NA)
Statistical analysis
  • Maintenance II - Arm A (Rituximab) vs Maintenance II - Arm B (Observation Only) · Stratified Long-rank · p = = 0.410 (Power at time of final analysis was less than 40%. Final analysis was not able to address its primary objective.) · Hazard ratio (hr): 0.76 · 95% CI 0.37 to 1.53
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs, and Infusion/Administration-related Reactions (IRRs/ARRs)

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Not all AEs were followed up for the randomized Observation arm. Only Serious AEs and AE grade 3-5 (obtained retrospectively) were collected for this arm. Therefore arms are not comparable overall.

Time frame:
From day of first rituximab induction dose up to day of disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs), Serious AEs, and Infusion/Administration-related Reactions (IRRs/ARRs)
ParticipantsAll Participants
Number of Participants with Adverse Events643
Number of Participants with Serious Adverse Events339
Number of Participants with IRRs/ARRs330
SecondaryEvent-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

Event-Free Survival was measured from the day of first rituximab Induction dose through Maintenance I and Maintenance II rituximab arm until the date of any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g. disease progression, toxicity, patient preference, initiation of new anti-lymphoma treatment, or death). Treatment discontinuation was considered as an event and was not applicable to the randomized observation arm.

Time frame:
From day of first rituximab induction dose up to day of any treatment failure, including disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)
Reported as:
Median · Months
Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
MonthsMaintenance II - Arm A (Rituximab)All Participants
Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia65.38 (60.98 to NA)24.99 (20.73 to 27.99)
SecondaryTime to Next Lymphoma Treatment (TNLT)

Time to next lymphoma treatment (TNLT) is defined as the time from date of first rituximab induction dose to the date date of first documented intake of any new antilymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc.).

Time frame:
From day of first rituximab induction dose up to any new lymphoma treatment (up to approximately 87 months)
Reported as:
Median · Months
Time to Next Lymphoma Treatment (TNLT)
MonthsMaintenance II - Arm A (Rituximab)Maintenance II - Arm B (Observation Only)All Participants
Time to Next Lymphoma Treatment (TNLT)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival

Overall survival from first induction treatment (OSRegist) is defined as the time from date of first rituximab induction dose to the date of death, irrespective of cause. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed.

Time frame:
From day of first rituximab induction dose up to death (up to approximately 87 months)
Reported as:
Median · Months
Overall Survival
MonthsAll Participants
Overall SurvivalNA (NA to NA)
SecondaryMaintenance II: Overall Survival

Overall survival from randomization (OSrand) is defined as the time from date of randomization to the date of death, irrespective of cause.

Time frame:
From randomization (Maintenance II) up to death (up to approximately 24 months)
Reported as:
Median · Months
Maintenance II: Overall Survival
MonthsMaintenance II - Arm A (Rituximab)Maintenance II - Arm B (Observation Only)
Maintenance II: Overall SurvivalNA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Partial or Complete Tumor Response (PR/CR) Assessment at End of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

Overall response rate is defined as the proportion of responders at the end of the Induction period. A responder is defined as a participant experiencing either CR or PR tumor response according to the Cheson response criteria for indolent lymphoma or the recommendations for Waldenström's macroglobulinemia.

Time frame:
From day of first rituximab induction dose up to end of induction period (up to approximately 8 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Partial or Complete Tumor Response (PR/CR) Assessment at End of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
Percentage of ParticipantsAll Participants
Percentage of Participants With Partial or Complete Tumor Response (PR/CR) Assessment at End of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia84.7 (81.8 to 87.3)
SecondaryMaintenance I: Percentage of Participants With Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
Time frame:
From day of first rituximab induction dose up to end of Maintenance I period (up to approximately 32 months)
Reported as:
Number · Percentage
Maintenance I: Percentage of Participants With Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
PercentageMaintenance I
Maintenance I: Percentage of Participants With Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia21.6 (17.4 to 26.2)
SecondaryProgression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

Progression free survival from first induction treatment (PFSregist) is defined as the time from date of first rituximab induction dose to the date of first documented disease progression or death by any cause, whichever occurs first.

Time frame:
From day of first rituximab induction dose up to disease progression or death, whichever occurs first (up to approximately 87 months)
Reported as:
Median · Months
Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
MonthsAll Participants
Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia59.33 (50.33 to 71.36)

Adverse events

Collected over From Baseline up to 47 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A10/138 (7.2%)59/138 (42.8%)133/138 (96.4%)
Arm B (Observation Only)8/138 (5.8%)58/138 (42%)133/138 (96.4%)
All Participants161/692 (23.3%)339/692 (49%)643/692 (92.9%)
Most frequent serious events
Showing 10 of 269
Most frequent serious events
EventArm AArm B (Observation Only)All Participants
PneumoniaInfections and infestations14/1386/13854/692
Febrile NeutropeniaBlood and lymphatic system disorders4/1382/13836/692
NeutropeniaBlood and lymphatic system disorders1/1386/13822/692
Lower respiratory tract infectionInfections and infestations1/1385/13810/692
Lung infectionInfections and infestations2/1384/1387/692
BronchitisInfections and infestations0/1384/1385/692
SepsisInfections and infestations3/1382/13818/692
Acute kidney injuryRenal and urinary disorders0/1383/1386/692
Infusion related reactionInjury, poisoning and procedural complications3/1380/1387/692
Urinary tract infectionInfections and infestations3/1382/13812/692
Most frequent other events
Showing 10 of 911
Most frequent other events
EventArm AArm B (Observation Only)All Participants
MeningitisInfections and infestations0/1380/1381/1
NeutropeniaBlood and lymphatic system disorders48/13851/138226/692
CoughRespiratory, thoracic and mediastinal disorders47/13824/138135/692
NauseaGastrointestinal disorders45/13837/138199/692
DiarrhoeaGastrointestinal disorders35/13828/138143/692
PyrexiaGeneral disorders32/13829/138159/692
FatigueGeneral disorders30/13819/138115/692
Neutrophil count decreasedInvestigations28/13829/138113/692
NasopharyngitisInfections and infestations29/13824/13872/692
AstheniaGeneral disorders27/13819/138113/692

Baseline characteristics

The Intent-to-Treat (ITT) population was used for the analysis of secondary efficacy parameters and Baseline variables. The randomised ITT population (ITTrand) included only randomised participants of Maintenance II period and was used for the analysis of the primary efficacy endpoint of PFS and the secondary analysis endpoint overall survival (OS)

Age, Continuous
Age, Continuous(years)All Participants
Mean64.6 ± 11.14
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female346
Male346
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Caucasian579
Black7
Asian5
Other32
Not applicable as per local regulation69
08

Study locations

180 sites
  • University "Mother Theresa" Hospital Center; Oncology Department
    Tirana, 1000, Albania
  • CEMIC Saavedra
    Buenos Aires, 1431, Argentina
  • Instituto Damic
    Cordoba, X5003DCE, Argentina
  • Hospital Privado de Comunidad; Oncology
    Mar Del Plata, 7600, Argentina
  • Lkh-Univ. Klinikum Graz; Klin. Abt. Für Hämatologie
    Graz, 8036, Austria
  • Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie
    Innsbruck, 6020, Austria
  • Kepler Universitätskliniken GmbH - Med Campus III; III. Medizinische Abteilung
    Linz, 4020, Austria
  • Landeskrankenhaus Rankweil; Interne E
    Rankweil, 6830, Austria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
    Wien, 1090, Austria
  • Centro de Tratamento Oncologico - CETRON
    Rio de janeiro, RJ 22250-906, Brazil
  • Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia
    Passo Fundo, RS 99010-260, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-003, Brazil
  • Centro de Pesquisas Oncologicas - CEPON
    Florianopolis, SC 88034-000, Brazil
  • Hospital de Cancer de Barretos
    Barretos, SP 14784-400, Brazil
  • Instituto de Ensino e Pesquisa Sao Lucas - IEP
    Sao Paulo, SP 01236-030, Brazil
  • Hospital das Clinicas - FMUSP; Hematologia
    Sao Paulo, SP 05403-000, Brazil
  • Hospital Santa Marcelina;Oncologia
    Sao Paulo, SP 08270-070, Brazil
  • UMHAT Dr Georgi Stranski; Hematology
    Pleven, 5800, Bulgaria
  • Tokuda Hospital Sofia; Hematology department
    Sofia, 1407, Bulgaria
  • UMHAT Alexandrovska EAD; Hematology
    Sofia, 1431, Bulgaria
  • Centro Javeriano de Oncología
    Bogota, Colombia
  • Fundacion Santa Fe de Bogotá
    Bogota, Colombia
  • Instituto Nacional de Cancerologia; Hematology
    Bogota, Colombia
  • Hospital Abel Gilbert Ponton; Oncology
    Guayaquil, EC090104, Ecuador
  • Teodoro Maldonado Carbo Hospital; Oncology Service
    Guayaquil, EC090150, Ecuador
  • Hospital Solca Portoviejo; Oncologia
    Portoviejo, EC130104, Ecuador
  • Hospital Solca Quito; Oncologia
    Quito, EC170124, Ecuador
  • Kasr Eieny Uni Hospital; Oncology (Nemrock)
    Cairo, 11562, Egypt
  • Centre Hospitalier Uni Ire; Service Des Maladies Du Sang
    Angers Cedex 9, 49933, France
  • CH Henri Mondor; Med Interne Neuro Endocrinologie
    Aurillac, 15000, France
  • Centre Hospitalier de La Cote Basque; Hematologie
    Bayonne, 64109, France
  • Hopital Jean Minjoz; Hematologie
    Besancon, 25030, France
  • Hopital Augustin Morvan; Hematologie
    Brest, 29609, France
  • Institut d'Hématologie de Basse Normandie
    Caen, 14000, France
  • CH Metropole de Savoie
    CHAMBERY Cedex, 73011, France
  • Chu Estaing; Hematologie Clinique Adultes
    Clermont Ferrand, 63003, France
  • Ch Sud Francilien; Hematologie Oncologie
    Corbeil Essonnes, 91000, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • Chu Site Du Bocage;Hematologie Clinique
    Dijon, 21079, France
  • Centre Hospitalier Departemental Les Oudairies
    La Roche Sur Yon, 85925, France
  • Hôpital Albert Michallon; Hematologie Clinique
    La Tronche, 38700, France
  • Hopital Andre Mignot; Hematologie - Oncologie
    Le Chesnay, 78157, France
  • Ch Du Mans; Medecine Hematologie Oncologie
    Le Mans, 72037, France
  • Hopital Claude Huriez; Hematologie
    Lille, 59037, France
  • Hopital Uni Ire Dupuytren; Hematologie
    Limoges, 87042, France
  • Hopital Nord; Laboratoire D'Hematologie
    Marseille, 13015, France
  • Hôpital Lapeyronie; Hématologie Oncologie Médicale
    Montpellier, 34295, France
  • Hopital Emile Muller; Hematologie
    Mulhouse, 68070, France
  • Hopital Hotel Dieu Et Hme; Clinique Dermatologique
    Nantes, 44093, France
  • Centre Antoine Lacassagne;B4 Hematologie Cancerologie
    Nice, 06189, France
  • Hopital Pitie Salpetriere; Hematologie Clinique
    Paris, 75651, France
  • Hopital De Haut Leveque; Hematologie Clinique
    Pessac, 33604, France
  • Centre Henri Becquerel; Hematologie
    Rouen, 76038, France
  • Hopital Purpan; Hematologie Clinique
    Toulouse, 31059, France
  • Gemeinschaftspraxis Dr. Bueckner und Dr. Nueckel
    Bochum, 44787, Germany
  • Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
    Darmstadt, 64283, Germany
  • St. Johannes Hospital; Abt. für Hämatologie und Onkologie
    Dortmund, 44137, Germany
  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
    Dresden, 01307, Germany
  • Gemeinschaftspraxis Dr. med. J. Mohm und Dr. med. G. Prange-Krex; Fachaerzte fuer Innere Medizin
    Dresden, 01307, Germany
  • Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik
    Greifswald, 17475, Germany
  • Internistisch-Onkologische Gemeinschaftspraxis; Dres. Rohrberg, Hurtz, Schma usw.
    Halle, 06110, Germany
  • OncoResearch Lerchenfeld GmbH
    Hamburg, 22081, Germany
  • Onkologische Schwerpunktpraxis (Eps-Gmbh)
    Jena, 07743, Germany
  • Dres. Richard Hansen Susanne Pfitzner-Dempfle und Manfred Reeb
    Kaiserslautern, 67655, Germany
  • Dres. Barbara Tschechne Stefanie Luft und Wolf-Oliver Jordan
    Lehrte, 31275, Germany
  • Onkologische Schwerpunktpraxis Lübeck
    Lübeck, 23562, Germany
  • Onkologische Gemeinschaftspraxis
    Magdeburg, 39104, Germany
  • Gemeinschaftspraxis Fr. Dr. med. Balser & Hr. Dr. med. Weidenbach
    Marburg, 35037, Germany
  • Dres. Michael Maasberg Marion Schmitz und Maria Theresia Keller
    Mayen, 56727, Germany
  • Klinikum Grosshadern der LMU
    Muenchen, 81377, Germany
  • Staedtisches Krankenhaus Muenchen-Schwabing, Haematologie & Onkolgie
    München, 80804, Germany
  • Hamatol Onkol Praxisgemeinschaft Dres H H-D Schick/D Schick
    München, 81241, Germany
  • Klinikum rechts der Isar der TU München; III. Medizinischen Klinik (Hämatologie/Onkologie)
    München, 81675, Germany
  • Praxis Dr.med. Jens Uhlig
    Naunhof, 04683, Germany
  • Oncologianova GmbH
    Recklinghausen, 45659, Germany
  • Klinik der Uni Regensburg; Hämatologie/Onkologie, Studienzentrale
    Regensburg, 93053, Germany
  • Dres. Andreas Hübner, Andreas Lück und Petra Bruhn
    Rostock, 18107, Germany
  • Dres. Ulrich Banhardt und Thomas Fietz
    Singen, 78224, Germany
  • Dres. Emil Höring Matthias Respondek und Ulrike Schwinger
    Stuttgart, 70190, Germany
  • General Hospital of Athens Evangelismos; Hematology
    Athens, 106 76, Greece
  • Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine
    Athens, 115 27, Greece
  • University Hospital of Ioannina; Hematology
    Ioannina, 455 00, Greece
  • University Hospital of Larissa; Hematology Dept.
    Larissa, 411100, Greece
  • University Hospital Of Patras; Dept. Of Internal Medicine-Hematology Division
    Patras, 265 00, Greece
  • Semmelweis University, First Dept of Medicine
    Budapest, 1083, Hungary
  • St Laszlo Hospital, Pharmacy
    Budapest, 1097, Hungary
  • National Institute of Oncology, A Dept of Internal Medicine
    Budapest, 1122, Hungary
  • Uni of Debrecen; 2Nd Clinic of Internal Medicine
    Debrecen, 4004, Hungary
  • University of Pecs, I st Dept of Internal Medicine
    Pecs, 7624, Hungary
  • A.O. Universitaria Federico II Di Napoli; Oncologia Ed Endocrinologia Clinica
    Napoli, Campania 80131, Italy
  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica
    Napoli, Campania 80131, Italy
  • Ospedale Cardarelli; Divisione Di Ematologia
    Napoli, Campania 80131, Italy
  • A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
    Bologna, Emilia-Romagna 40138, Italy
  • A.O.U. Policlinico di Modena-Dipartimento di Medicina Diagnostica, Clinica e di Sanità pubblica
    Modena, Emilia-Romagna 41100, Italy
  • A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol
    Roma, Lazio 00161, Italy
  • A.O. Universitaria S. Martino Di Genova; Ematologia 1
    Genova, Liguria 16132, Italy
  • Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora
    Milano, Lombardia 20122, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
    Milano, Lombardia 20162, Italy
  • A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1
    Torino, Piemonte 10126, Italy

Showing the first 100 of 180 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner CM, Zaja F, Robson S, MacGregor L, Tschopp RR, Nick S, Dreyling M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. Haematologica. 2022 Feb 1;107(2):500-509. doi: 10.3324/haematol.2020.274803. PubMed 34134469 ↗
  • Theodore-Oklota C, Humphrey L, Wiesner C, Schnetzler G, Hudgens S, Campbell A. Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. Patient Prefer Adherence. 2016 Sep 13;10:1767-1776. doi: 10.2147/PPA.S108489. eCollection 2016. PubMed 27695295 ↗
  • Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014 Jul;17(7):459-68. doi: 10.3111/13696998.2014.914033. Epub 2014 May 7. PubMed 24720836 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Jun 2018, 77 months.

Results were first posted in Aug 2019, 1 year 2 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 77 months is above that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2011
First posted
Oct 28, 2011
StartActual
Dec 20, 2011
Primary completionActual
Jun 2, 2018
CompletionActual
Jun 2, 2018
Results first posted
Aug 6, 2019
Last update
Aug 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01461928
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 28, 2011
Start date
Dec 20, 2011
Primary completion
Jun 2, 2018
Completion
Jun 2, 2018
Results posted
Aug 6, 2019
Last update
Aug 6, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion